Jan Gettemans Selected Research

Gelsolin

1/2019	Nanobody interaction unveils structure, dynamics and proteotoxicity of the Finnish-type amyloidogenic gelsolin variant.
1/2019	The role of gelsolin domain 3 in familial amyloidosis (Finnish type).
1/2017	AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model.
1/2017	AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model.
12/2016	Non-Invasive Imaging of Amyloid Deposits in a Mouse Model of AGel Using 99mTc-Modified Nanobodies and SPECT/CT.
5/2015	An ER-directed gelsolin nanobody targets the first step in amyloid formation in a gelsolin amyloidosis mouse model.
10/2014	Chaperone nanobodies protect gelsolin against MT1-MMP degradation and alleviate amyloid burden in the gelsolin amyloidosis mouse model.
9/2007	Downregulation of gelsolin family proteins counteracts cancer cell invasion in vitro.
12/2002	Gelsolin-induced epithelial cell invasion is dependent on Ras-Rac signaling.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jan Gettemans Research Topics

Disease

23	Neoplasms (Cancer) 01/2021 - 12/2002
7	Amyloidosis 01/2019 - 10/2014
4	Breast Neoplasms (Breast Cancer) 01/2021 - 12/2013
4	Neoplasm Metastasis (Metastasis) 01/2020 - 05/2007
4	Prostatic Neoplasms (Prostate Cancer) 01/2020 - 05/2008
3	Carcinogenesis 01/2019 - 05/2009
3	Charcot-Marie-Tooth Disease (Peroneal Muscular Atrophy) 08/2012 - 06/2004
2	Type II Lattice Corneal Dystrophy 01/2019 - 12/2016
1	Osteolysis 03/2019
1	Carcinoma (Carcinomatosis) 03/2019
1	Familial Amyloidosis (Hereditary Amyloidosis) 01/2019
1	Amyloid Plaque 12/2016
1	Metrorrhagia (Spotting) 10/2016
1	T-Cell Leukemia (Leukemia, T Cell) 10/2016
1	Type 2I Charcot-Marie-Tooth disease 08/2012
1	Type II Distal Hereditary Motor Neuropathy 06/2004
1	Neurodegenerative Diseases (Neurodegenerative Disease) 06/2004
1	Type 2F Charcot-Marie-Tooth disease 06/2004

Drug/Important Bio-Agent (IBA)

14	Proteins (Proteins, Gene)FDA Link 01/2019 - 06/2004
10	Single-Domain AntibodiesIBA 01/2021 - 12/2013
9	GelsolinIBA 01/2019 - 12/2002
5	plastinIBA 03/2019 - 04/2005
4	Amyloid (Amyloid Fibrils)IBA 01/2017 - 10/2014
3	CortactinIBA 06/2018 - 04/2014
3	fascinIBA 10/2016 - 04/2014
3	Actins (F Actin)IBA 04/2014 - 01/2010
3	matrigelIBA 12/2013 - 05/2007
3	Small Heat-Shock ProteinsIBA 08/2012 - 06/2004
2	Phosphotransferases (Kinase)IBA 01/2021 - 01/2020
2	CalciumIBA 03/2019 - 01/2019
2	Matrix Metalloproteinase 14 (MT1-MMP)IBA 01/2017 - 10/2014
2	Pharmaceutical PreparationsIBA 06/2016 - 05/2007
2	Collagen Type I (Type I Collagen)IBA 05/2009 - 05/2007
2	Protein Isoforms (Isoforms)IBA 05/2009 - 05/2008
1	SpectrinIBA 01/2020
1	VA 061 (VA061)IBA 01/2020
1	CateninsIBA 01/2020
1	Microfilament Proteins (Actin Binding Proteins)IBA 01/2020
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2020
1	AndrogensIBA 01/2020
1	Messenger RNA (mRNA)IBA 03/2019
1	Conditioned Culture MediaIBA 03/2019
1	PeroxiredoxinsIBA 03/2019
1	Oncogene Proteins (Oncogene Protein)IBA 01/2019
1	FurinIBA 01/2019
1	Proline (L-Proline)FDA Link 06/2018
1	SurvivinIBA 12/2016
1	LigandsIBA 06/2016
1	Cytoskeletal ProteinsIBA 01/2016
1	AntigensIBA 04/2014
1	AntibodiesIBA 04/2014
1	Type III Secretion SystemsIBA 12/2013
1	Small Interfering RNA (siRNA)IBA 05/2009
1	Tumor Biomarkers (Tumor Markers)IBA 05/2007
1	SynteninsIBA 05/2007
1	LipidsIBA 11/2005
1	lysophosphatidic acidIBA 11/2005
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 06/2004

Therapy/Procedure

6	Therapeutics 01/2021 - 12/2010
1	Immunomodulation 12/2013
1	Activator Appliances (Function Activator) 05/2009